Bird invests $10m. in 11 projects

The Bird Foundation approved a $10 million investment in 11 joint US-Israeli development projects, the fund said Sunday.

June 26, 2006 09:08


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Bird Foundation (Israel-U.S. Binational Industrial Research and Development) approved a $10 million investment in 11 joint US-Israeli development projects, the fund said Sunday. The investment spans the life sciences, communications, homeland security and alternative energy industries, linking Israeli companies with US partners in those sectors. Participants in the projects include established companies such as M-Systems, Spansion and Ibasis, as well as start-ups Rosetta Genomics, GreenFuel Technologies, Enforsys, GlobalSim and Chromadex, covering research from the development of a liver cancer drug, to a project aimed at producing biofuel from algae, and capturing CO2 emissions from coal power plants.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection